Clinical Trial Update: ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of ABT-888 (veliparib) in patients with refractory solid tumors or hematologic cancers conducted by NIH Clinical Center; the trial status is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• ABT-888 (veliparib)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED